National Research (National Research) ROCE % : 56.71% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is National Research ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. National Research's annualized ROCE % for the quarter that ended in Dec. 2023 was 56.71%.

National Research ROCE % Historical Data

The historical data trend for National Research's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

National Research ROCE % Chart

National Research Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

63.86

49.67

45.95

41.11

44.55

National Research Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															40.88	37.91	38.92	45.53	56.71

National Research ROCE % Calculation

National Research's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	40.824	/	( ( (130.461 - 33.417)	+	(122.437 - 36.203) )	/ 2 )
	=	40.824	/	( (97.044	+	86.234)	/ 2 )
	=	40.824	/	91.639
	=	44.55 %

National Research's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	46.944	/	( ( (120.136 - 40.805)	+	(122.437 - 36.203) )	/ 2 )
	=	46.944	/	( ( 79.331	+	86.234 )	/ 2 )
	=	46.944	/	82.7825
	=	56.71 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

National Research (NAS:NRC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

National Research ROCE % Related Terms

Thank you for viewing the detailed overview of National Research's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

National Research (National Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » National Research Corp (NAS:NRC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1245 Q Street, Lincoln, NE, USA, 68508

Website

https://www.nrchealth.com

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. The solutions are offered at an enterprise level through the Voice of the Customer platform, The Governance Institute, and legacy Experience solutions. It operates in the United States and Canada, of which key revenue is derived from the United States.

Executives

Amandla Mk Trust	10 percent owner	C/O THE BRYN MAWR TRUST COMPANY OF DELAW, 20 MONTCHANIN RD, SUITE 100, GREENVILLE DE 19807
Common Property Trust	10 percent owner	709 PIER 2, LINCOLN NE 68528
Parul Bhandari	director	1775 I STREET NW, SUITE 910, WASHINGTON DC 20006
Stephen H Lockhart	director	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Penny Ann Wheeler	director	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Donald M Berwick	director	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Jona S Raasch	officer: Vice President and COO
Kevin R Karas	officer: SVP Finance, CFO, Treas & Secy	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Michael & Karen Hays Grandchildren's Trust Dated March 9, 2009	10 percent owner	C/O BESSEMER TRUST COMPANY OF DELAWARE, 1007 N. ORANGE ST., SUITE 1450, WILMINGTON DE 19801
Joann M Martin	director	6221 ANDREW COURT, LINCOLN NE 68512
Helen Hrdy	officer: Chief Growth Officer	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Steven D. Jackson	officer: President	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
John N Nunnelly	director	P.O. BOX 2175, AMHERST MA 01004
Barbara Mowry	director	P.O. BOX 103115, DENVER CO 80250
Michael Hays	director, 10 percent owner, officer: President and CEO	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508